IVPH -- INNOVIVE Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVPH -- INNOVIVE Pharmaceuticals

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bookert11 who wrote (109)	6/9/2008 5:40:52 PM
From: stunner	Read Replies (1) of 117

Thanks for sending over the Griffin report. CYTRX picked up IVPH at b-stearns prices to replace it's pipeline. They've got $45M in cash and the ALS drug is going nowhere for a year and will probably not be in another clinical trial until the Inno pipeline is well advanced, if it is ever developed. With minimal spending on the ALS drug, the cash focus will be on IVPH's pipeline. Nice to see that the sale milestones for shareholder payment were not ridiculously high, and even tamibarotene should hit the early numbers in the 1st year of sales. Still, that is at least 3 years away. So basically, wait for the merger, hold or sell the remnants of IVPH and maybe in 3 years a surprise check will be in the mail...although I doubt it. What happens if cytrx sells rights to IVPH406 or tamibarotene, do the IVPH shareholders get anything? Maybe I missed that in the 8-k. Nice that the news didn't even pop up under IVPH stock symbol or their website...had to get the news off this site (thank you by the way). I find that ridiculous and, in some way, possibly illegal for a publicly reporting company.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next